Metals and metal compounds in carcinogenesis

In Vivo

Volumn 17, Issue 6, 2003, Pages 529-539

  Desoize, Bernard ^a  

^a UNIVERSITÉ DE REIMS CHAMPAGNE ARDENNE   (France)

Author keywords

Arsenic; Cadmium; Carcinogenesis; Chromium; Copper; Manganese; Nickel; ROS; Vanadium; Zinc

Indexed keywords

ARSENIC; CARCINOGEN; CERULOPLASMIN; CHEMICAL MUTAGEN; CHROMIUM; COPPER; CYCLOSPORIN A; CYTOCHROME C; FERRITIN; HISTONE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IRON; MANGANESE; METAL; METAL DERIVATIVE; NICKEL; PROTEIN KINASE C; REACTIVE OXYGEN METABOLITE; TAMOXIFEN; TUMOR NECROSIS FACTOR ALPHA; VANADIUM;

ACETYLATION; CARCINOGENESIS; CELL METABOLISM; CELL TRANSFORMATION; DNA DAMAGE; DNA METHYLATION; GENE EXPRESSION; HUMAN; LONG TERM EXPOSURE; NONHUMAN; OXIDATIVE STRESS; REVIEW; TOXICITY TESTING;

EID: 0842308068     PISSN: 0258851X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (126)

1. Domingo JL: Metal-induced developmental toxicity in mammals: A review. J Toxicol Environ Health 42: 123-141, 1994.
2. Gebel TW: Confounding variables in the environmental toxicology of arsenic. Toxicology 144: 155-162, 2000.
3. Gebel TW: Unanswered questions in arsenic toxicology. J Environ Pathol Toxicol Oncol 20: 299-309, 2001.
4. Bode AM and Dong Z: The paradox of arsenic: Molecular mechanisms of cell transformation and chemotherapeutic effects. Crit Rev Oncol Hematol 42: 5-24, 2002.
5. Meng ZQ and Meng NY: Effects of arsenic on blast transformation and DNA synthesis of human blood lymphocytes. Chemosphere 41: 115-119, 2000.
6. Simeonova PP and Luster MI: Arsenic carcinogenicity: Relevance of c-Src activation. Mol Cell Biochem 234-235: 277-282, 2002.
7. Germolec DR, Spalding J, Yu HS, Chen GS, Simeonova PP, Humble MC, Bruccoleri A, Boorman GA, Foley JF, Yoshida T and Luster MI: Arsenic enhancement of skin neoplasia by chronic stimulation of growth factors. Am J Pathol 153: 1775-1785, 1998.
8. Wu W, Graves LJ, Jaspers I, Devlin RB, Reed W and Samet JM: Activation of the EGF receptor signaling pathway in human airway epithelial cells exposed to metals. Am J Physiol 277: L924-L931, 1999.
9. Trouba KJ, Hamadeh HK, Amin RP and Germolec DR: Oxidative stress and its role in skin disease. Antioxid Redox Signal 4: 665-673, 2002.
10. Simeonova PP and Luster MI: Mechanisms of arsenic carcinogenicity: Genetic or epigenetic mechanisms? J Environ Pathol Toxicol Oncol 19: 281-286, 2000.
11. Simeonova PP, Wang S, Toriuma W, Kommineni V, Matheson J, Unimye N, Kayama F, Ding M, Vallyathan V and Luster MI: Arsenic mediates cell proliferation and gene expression in the bladder epithelium: Association with activating protein-1 transactivation. Cancer Res 60: 3445-3453, 2000.
12. Roussel RR and Barchowsky A: Arsenic inhibits NF-kappaB-mediated gene transcription by blocking IkappaB kinase activity and IkappaBalpha phosphorylation and degradation. Arch Biochem Biophys 377: 204-212, 2000.
13. Angel P and Karin M: The role of Jun, Fos and the AP-1 complex in cell-proliferation and transformation. Biochim Biophys Acta 1072: 129-157, 1991.
14. Kharbanda S, Saxena S, Yoshida K, Pandey P, Kaneki M, Wang Q, Cheng K, Chen YN, Campbell A, Sudha T, Yuan ZM, Narula J, Weichselbaum R, Nalin C and Kufe D: Translocation of SAPK/JNK to mitochondria and interaction with Bcl-x(L) in response to DNA damage. J Biol Chem 275: 322-327, 2000.
15. Davis RJ: MAPKs: New JNK expands the group. Trends Biochem Sci 19: 470-473, 1994.
16. Newton AC: Protein kinase C. Seeing two domains. Curr Biol 5: 973-976, 1995.
17. Karin M and Delhase M: The I kappa B kinase (IKK) and NF-kappa B: Key elements of proinflammatory signalling. Semin Immunol 12: 85-98, 2000.
18. Schulze-Osthoff K, Ferrari D, Riehemann K and Wesselborg S: Regulation of NF-kappa B activation by MAP kinase cascades. Immunobiology 198: 35-49, 1997.
19. Gilmore TD: Clinically relevant findings. J Clin Invest 100: 2935-2936, 1997.
20. Li JJ, Westergaard C, Ghosh P and Colburn NH: Inhibitors of both nuclear factor-kappaB and activator protein-1 activation block the neoplastic transformation response. Cancer Res 57: 3569-3576, 1997.
21. Cai X, Shen YL, Zhu Q, Jia PM, Yu Y, Zhou L, Huang Y, Zhang JW, Xiong SM, Chen SJ, Wang ZY, Chen Z and Chen GQ: Arsenic trioxide-induced apoptosis and differentiation are associated respectively with mitochondrial transmembrane potential collapse and retinoic acid signaling pathways in acute promyelocytic leukemia. Leukemia 14: 262-270, 2000.
22. Huang C, Ma WY, Li J and Dong Z: Arsenic induces apoptosis through a c-Jun NH2-terminal kinase-dependent, p53-independent pathway. Cancer Res 59: 3053-3058, 1999.
23. Pu YS, Hour TC, Chen J, Huang CY, Guan JY and Lu SH: Arsenic trioxide as a novel anticancer agent against human transitional carcinoma - Characterizing its apoptotic pathway. Anticancer Drugs 13: 293-300, 2002.
24. Li YM and Broome JD: Arsenic targets tubulins to induce apoptosis in myeloid leukemia cells. Cancer Res 59: 776-780, 1999.
25. Radha S and Natarajan AT: Sodium arsenite-induced chromosomal aberrations in the Xq arm of Chinese hamster cell lines. Mutagenesis 13: 229-234, 1998.
26. Sampayo-Reyes A, Zakharyan RA, Healy SM and Aposhian HV: Monomethylarsonic acid reductase and monomethylarsonous acid in hamster tisssue. Chem Res Toxicol 13: 1181-1186, 2000.
27. Stohs SJ and Bagchi D: Oxidative mechanisms in the toxicity of metal ions. Free Radic Biol Med 18: 321-336, 1995.
28. Abe T, Yamamoto O, Gotoh S, Yan Y, Todaka N and Higashi K: Cadmium-induced mRNA expression of Hsp32 is augmented in metallothionein-I and -II knock-out mice. Arch Biochem Biophys 382: 81-88, 2000.
29. Waalkes MP: Cadmium carcinogenesis in review. J Inorg Biochem 79: 241-244, 2000.
30. Yuan C, Kadiiska M, Achanzar WE, Mason RP and Waalkes MP: Possible role of caspase-3 inhibition in cadmium-induced blockage of apoptosis. Toxicol Appl Pharmacol 164: 321-329, 2000.
31. Galaris D and Evangelou A: The role of oxidative stress in mechanisms of metal-induced carcinogenesis. Crit Rev Oncol Hematol 42: 93-103, 2002.
32. Medeiros MG, Rodrigues AS, Batoreu MC, Laires A, Rueff J and Zhitkovich A: Elevated levels of DNA-protein crosslinks and micronuclei in peripheral lymphocytes of tannery workers exposed to trivalent chromium. Mutagenesis 18: 19-24, 2003.
33. Andrew AS, Karagas MR and Hamilton JW: Decreased DNA repair gene expression among individuals exposed to arsenic in United States drinking water. Int J Cancer 104: 263-268, 2003.
34. Snow ET: Effects of chromium on DNA replication in vitro. Environ Health Perspect 102 Suppl 3: 41-44, 1994.
35. Carlisle DL, Pritchard DE, Singh J and Patierno SR: Chromium (VI) induces p53-dependent apoptosis in diploid human lung and mouse dermal fibroblasts. Mol Carcinog 28: 111-118, 2000.
36. Carlisle DL, Pritchard DE, Singh J, Owens BM, Blankenship LJ, Orenstein JM and Patierno SR: Apoptosis and P53 induction in human lung fibroblasts exposed to chromium (VI): Effect of ascorbate and tocopherol. Toxicol Sci 55: 60-68, 2000.
37. WHO World Health Organization. Trace Elements in Human Nutrition. Series 532, Genève: WHO, 1973.
38. Gerber GB, Leonard A and Hantson P: Carcinogenicity, mutagenicity and teratogenicity of manganese compounds. Crit Rev Oncol Hematol 42: 25-34, 2002.
39. Oehme FW: Toxicity of Heavy Metals in the Environment. New York, Basel, Marcel Dekker Inc, 1978.
40. Keen CL and Leach RM: Manganese. In: Handbook on Toxicity of Inorganic Compounds (Seiler HG, Sigel H and Sigel A ed). New York, Basel, Marcel Dekker Inc, 1988, pp 405-414.
41. Van De Sande JH, McIntosh LP and Jovin TM: Mn2+ and other transition metals at low concentration induce the right-to-left helical transformation of poly[d(G-C)]. EMBO J 1: 777-782, 1982.
42. Furst A: Tumorigenic effect of an organomanganese compound on F344 rats and Swiss albino mice. J Natl Cancer Inst 60: 1171-1173, 1978.
43. Bray TM and Bettger WJ: The physiological role of zinc as an antioxidant. Free Radic Biol Med 8: 281-291, 1990.
44. Klotz LO, Kroncke KD, Buchczyk DP and Sies H: Role of copper, zinc, selenium and tellurium in the cellular defense against oxidative and nitrosative stress. J Nutr 133: 1448S-1451S, 2003.
45. Chevion M, Korbashi P, Katzhandler J and Saltman P: Zinc - A redox-inactive metal provides a novel approach for protection against metal-mediated free radical induced injury: Study of paraquat toxicity in E. coli. Adv Exp Med Biol 264: 217-222, 1990.
46. Har-El R and Chevion M: Zinc(II) protects against metal-mediated free radical induced damage: Studies on single and double-strand DNA breakage. Free Radic Res Commun 12-13 Pt 2: 509-515, 1991.
47. Chromium, nickel and welding. In: 49, Monographs on the Evaluation of Carcinogenic Risks to Humans International Agency for Research on Cancer. IARC Sci Publ 1990.
48. Bennett BG: Environmental nickel pathways to man. IARC Sci Publ 487-495, 1984.
49. Denkhaus E and Salnikow K: Nickel essentiality, toxicity, and carcinogenicity. Crit Rev Oncol Hematol 42: 35-56, 2002.
50. Sunderman FW Jr.: Organ and species specificity in nickel subsulfide carcinogenesis. Basic Life Sci 24: 107-127, 1983.
51. Sunderman FW Jr.: Nasal toxicity, carcinogenicity, and olfactory uptake of metals. Ann Clin Lab Sci 31: 3-24, 2001.
52. Fletcher GG, Rossetto FE, Turnbull JD and Nieboer E: Toxicity, uptake, and mutagenicity of particulate and soluble nickel compounds. Environ Health Perspect 102 Suppl 3: 69-79, 1994.
53. Lee YW, Klein CB, Kargacin B, Salnikow K, Kitahara J, Dowjat K, Zhitkovich A, Christie NT and Costa M: Carcinogenic nickel silences gene expression by chromatin condensation and DNA methylation: A new model for epigenetic carcinogens. Mol Cell Biol 15: 2547-2557, 1995.
54. Broday L, Peng W, Kuo MH, Salnikow K, Zoroddu M and Costa M: Nickel compounds are novel inhibitors of histone H4 acetylation. Cancer Res 60: 238-241, 2000.
55. Salnikow K, Wang S and Costa M: Induction of activating transcription factor 1 by nickel and its role as a negative regulator of thrombospondin I gene expression. Cancer Res 57: 5060-5066, 1997.
56. Goebeler M, Meinardus-Hager G, Roth J, Goerdt S and Sorg C: Nickel chloride and cobalt chloride, two common contact sensitizers, directly induce expression of intercellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1), and endothelial leukocyte adhesion molecule (ELAM-1) by endothelial cells. J Invest Dermatol 100: 759-765, 1993.
57. Lin X, Dowjat WK and Costa M: Nickel-induced transformation of human cells causes loss of the phosphorylation of the retinoblastoma protein. Cancer Res 54: 2751-2754, 1994.
58. Miller AC, Blakely WF, Livengood D, Whittaker T, Xu J, Eknik JW, Hamilton MM, Parlette E, John TS, Gerstenberg HM and Hsu H: Transformation of human osteoblast cells to the tumorigenic phenotype by depleted uranium-uranyl chloride. Environ Health Perspect 106: 465-471, 1998.
59. Swierenga SH, Whitfield JF and Gillan DJ: Alteration by malignant transformation of the calcium requirements for cell proliferation in vitro. J Natl Cancer Inst 57: 125-129, 1976.
60. Athar M, Hasan SK and Srivastava RC: Evidence for the involvement of hydroxyl radicals in nickel mediated enhancement of lipid peroxidation: Implications for nickel carcinogenesis. Biochem Biophys Res Commun 147: 1276-1281, 1987.
61. Eisses JF and Kaplan JH: Molecular characterization of hCTR1, the human copper uptake protein. J Biol Chem 277: 29162-29171, 2002.
62. Theophanides T and Anastassopoulou J: Copper and carcinogenesis. Crit Rev Oncol Hematol 42: 57-64, 2002.
63. Burkitt MJ: Copper - DNA adducts. Methods Enzymol 234: 66-79, 1994.
64. Maskos K: The interaction of metal ions with nucleic acids. NMR study of the copper(II) interaction with inosine derivatives. Acta Biochim Pol 28: 317-335, 1981.
65. Sakano S, Oikawa S, Murata M, Hiraku Y, Kojima N and Kawanishi S: Mechanism of metal-mediated DNA damage induced by metabolites of carcinogenic 2-nitropropane. Mutat Res 479: 101-111, 2001.
66. Milne L, Nicotera P, Orrenius S and Burkitt MJ: Effects of glutathione and chelating agents on copper-mediated DNA oxidation: Pro-oxidant and antioxidant properties of glutathione. Arch Biochem Biophys 304: 102-109, 1993.
67. Obata H, Sawada N, Isomura H and Mori M: Abnormal accumulation of copper in LEC rat liver induces expression of p53 and nuclear matrix-bound p21(waf 1/cip 1). Carcinogenesis 17: 2157-2161, 1996.
68. Davis CD and Newman S: Inadequate dietary copper increases tumorigenesis in the Min mouse. Cancer Lett 159: 57-62, 2000.
69. Nriagu JO: History, occurrence and uses of vanadium. In: Vanadium in the Environment (Nriagu, JO, ed). New-York, Wiley, 1998, pp 1-24.
70. Barceloux DG: Vanadium. J Toxicol Clin Toxicol 37: 265-278, 1999.
71. Scheving LA, Thomas JR and Zhang L: Regulation of intestinal tyrosine phosphorylation and programmed cell death by peroxovanadate. Am J Physiol 277: C572-C579, 1999.
72. Evangelou AM: Vanadium in cancer treatment. Crit Rev Oncol Hematol 42: 249-365, 2002.
73. Halliwell B and Gutteridge JMC: Free radicals 'reactive species' and toxicology. 544-616, (Halliwell B, Gutteridge JMC). Oxford University Press, 1999.
74. Chen F and Shi X: Intracellular signal transduction of cells in response to carcinogenic metals. Crit Rev Oncol Hematol 42: 105-121, 2002.
75. Jacobs A: Low molecular weight intracellular iron transport compounds. Blood 50: 433-439, 1977.
76. Stevens RG, Graubard BI, Micozzi MS, Neriishi K and Blumberg BS: Moderate elevation of body iron level and increased risk of cancer occurrence and death. Int J Cancer 56: 365-369, 1994.
77. Chitambar CR, Massey EJ and Seligman PA: Regulation of transferrin receptor expression on human leukemic cells during proliferation and induction of differentiation. Effects of gallium and dimethylsulfoxide. J Clin Invest 72: 1314-1325, 1983.
78. Trinder D, Zak O and Aisen P: Transferrin receptor-independent uptake of differic transferrin by human hepatoma cells with antisense inhibition of receptor expression. Hepatology 23: 1512-1520, 1996.
79. Stevens RG, Jones DY, Micozzi MS and Taylor PR: Body iron stores and the risk of cancer. N Engl J Med 319: 1047-1052, 1988.
80. Kawabata H, Germain RS, Vuong PT, Nakamaki T, Said JW and Koeffler HP: Transferrin receptor 2-alpha supports cell growth both in iron-chelated cultured cells and in vivo. J Biol Chem 275: 16618-16625, 2000.
81. Woodbury RG, Brown JP, Yeh MY, Hellstrom I and Hellstrom KE: Identification of a cell surface protein, p97, in human melanomas and certain other neoplasms. Proc Natl Acad Sci USA 77: 2183-2187, 1980.
82. Brown JP, Woodbury RG, Hart CE, Hellstrom I and Hellstrom KE: Quantitative analysis of melanoma-associated antigen p97 in normal and neoplastic tissues. Proc Natl Acad Sci USA 78: 539-543, 1981.
83. Neckers LM and Cossman J: Transferrin receptor induction in mitogen-stimulated human T lymphocytes is required for DNA synthesis and cell division and is regulated by interleukin 2. Proc Natl Acad Sci USA 80: 3494-3498, 1983.
84. Kameyama K, Takezaki S, Kanzaki T and Nishiyama S: HLA-DR and melanoma-associated antigen (p97) expression during the cell cycle in human melanoma cell lines, and the effects of recombinant gamma-interferon: Two-color flow cytometric analysis. J Invest Dermatol 87: 313-318, 1986.
85. Kwok JC and Richardson DR: The iron metabolism of neoplastic cells: Alterations that facilitate proliferation? Crit Rev Oncol Hematol 42: 65-78, 2002.
86. Darnell G and Richardson DR: The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents III: The effect of the ligands on molecular targets involved in proliferation. Blood 94: 781-792, 1999.
87. Vandewalle B, Hornez L, Revillion F and Lefebvre J: Secretion of transferrin by human breast cancer cells. Biochem Biophys Res Commun 163: 149-154, 1989.
88. Poola I: An estrogen inducible 104 kDa chaperone glycoprotein binds ferric iron containing proteins: A possible role in intracellular iron trafficking. FEBS Lett 416: 139-142, 1997.
89. Kaplan J and O'Hallaran TV: Iron metabolism in eukaryotes: Mars and Venus at it again. Science 271: 1510-1512, 1996.
90. Osaki S, Johnson DA and Frieden E: The possible significance of the ferrous oxidase activity of ceruloplasmin in normal human serum. J Biol Chem 241: 2746-2751, 1966.
91. Richardson DR: Potential of iron chelators as effective antiproliferative agents. Can J Physiol Pharmacol 75: 1164-1180, 1997.
92. Niklinski J and Furman M: Clinical tumour markers in lung cancer. Eur J Cancer Prev 4: 129-138, 1995.
93. Munro HN and Linder MC: Ferritin: Structure, biosynthesis, and role in iron metabolism. Physiol Rev 58: 317-396, 1978.
94. Broxmeyer HE, Cooper S, Levi S and Arosio P: Mutated recombinant human heavy-chain ferritins and myelosuppression in vitro and in vivo: A link between ferritin ferroxidase activity and biological function. Proc Natl Acad Sci USA 88: 770-774, 1991.
95. Anastassopoulou J and Theophanides T: Magnesium-DNA interactions and the possible relation of magnesium to carcinogenesis. Irradiation and free radicals. Crit Rev Oncol Hematol 42: 79-91, 2002.
96. Black CB and Cowan JA: Magnesium-dependent enzymes in general methodology. In: The Biological Chemistry of Magnesium (Cowan, J. A., ed). New York, VCH Publishers, Ink, 1995, pp 159-183.
97. Pelletier H, Sawaya MR, Kumar A, Wilson SH and Kraut J: Structures of ternary complexes of rat DNA polymerase beta, a DNA template-primer, and ddCTP. Science 264: 1891-1903, 1994.
98. Chiu TK and Dickerson RE: A crystal structures of B-DNA reveal sequence-specific binding and groove-specific bending of DNA by magnesium and calcium. J Mol Biol 301: 915-945, 2000.
99. Bodell WJ: Effect of cations on the formation of DNA alkylation products in DNA reacted with 1-(2-Chloroethyl)-1-nitrosourea. Chem Res Toxicol 12: 965-970, 1999.
100. Craig ML, Suh WC and Record MT Jr.: HO. and DNase I probing of E sigma 70 RNA polymerase - Lambda PR promoter open complexes: Mg2+ binding and its structural consequences at the transcription start site. Biochemistry 34: 15624-15632, 1995.
101. Bronzetti G, Aretini P, Ambrosini C, Cini M, Fiorio R, Caltavuturo L, Croce CD and Panunzio M: Antimutagenesis studies of magnesium and calcium salts. J Environ Pathol Toxicol Oncol 19: 401-413, 2000.
102. Wolf FI, Torsello A, Fasanella S and Cittadini A: Cell physiology of magnesium. Mol Aspects Med 24: 11-26, 2003.
103. Cittadini A, Wolf FI, Bossi D and Calviello G: Magnesium in normal and neoplastic cell proliferation: State of the art on in vitro data. Magnes Res 4: 23-33, 1991.
104. Durlach J, Bara M, Guiet-Bara A and Collery P: Relationship between magnesium, cancer and carcinogenic or anticancer metals. Anticancer Res 6: 1353-1361, 1986.
105. Kimura C, Zhao QL, Kondo T, Amatsu M and Fujiwara Y: Mechanism of UV-induced apoptosis in human leukemia cells: Roles of Ca2+/Mg(2+)-dependent endonuclease, caspase-3, and stress-activated protein kinases. Exp Cell Res 239: 411-422, 1998.
106. Kaminskas E and Li JC: DNA fragmentation in permeabilized cells and nuclei. The role of (Ca2+ + Mg2+)-dependent endodeoxyribonuclease. Biochem J 261: 17-21, 1989.
107. Weglicki WB, Kramer JH, Mak IT, Komarov AM and Philips TM: Proinflammatory neuropeptides in magnesium deficiency. In: Metal Ions in Biology and Medicine (Centeno JA, Collery P and Vernet G ed). Paris, John Libbey Eurotext, 2000, pp 472-474.
108. Tiekink ER: Antimony and bismuth compounds in oncology. Crit Rev Oncol Hematol 42: 217-224, 2002.
109. Gebel T: Arsenic and antimony: Comparative approach on mechanistic toxicology. Chem Biol Interact 107: 131-144, 1997.
110. Galaris D, Cadenas E and Hochstein P: Glutathione-dependent reduction of peroxides during ferryl- and met-myoglobin interconversion: A potential protective mechanism in muscle. Free Radic Biol Med 6: 473-478, 1989.
111. Bellomo G, Vairetti M, Stivala L, Mirabelli F, Richelmi P and Orrenius S: Demonstration of nuclear compartmentalization of glutathione in hepatocytes. Proc Natl Acad Sci USA 89: 4412-4416, 1992.
112. Hwang C, Sinskey AJ and Lodish HF: Oxidized redox state of glutathione in the endoplasmic reticulum. Science 257: 1496-1502, 1992.
113. Jain A, Alvi NK, Parish JH and Hadi SM: Oxygen is not required for degradation of DNA by glutathione and Cu(II). Mutat Res 357: 83-88, 1996.
114. Hartwig A: Carcinogenicity of metal compounds: Possible role of DNA repair inhibition. Toxicol Lett 102-103: 235-239, 1998.
115. Lynn S, Yew FH, Hwang JW, Tseng MJ and Jan KY: Glutathione can rescue the inhibitory effects of nickel on DNA ligation and repair synthesis. Carcinogenesis 15: 2811-2816, 1994.
116. Baeuerle PA and Baltimore D: NF-kappa B: Ten years after. Cell 87: 13-20, 1996.
117. Brand K, Page S, Rogler G, Bartsch A, Brandl R, Knuechel R, Page M, Kaltschmidt C, Baeuerle PA and Neumeier D: Activated transcription factor nuclear factor-kappa B is present in the atherosclerotic lesion. J Clin Invest 97: 1715-1722, 1996.
118. Rahmsdorf HJ and Herrlich P: Regulation of gene expression by tumor promoters. Pharmacol Ther 48: 157-188, 1990.
119. Ashkenazi A and Dixit VM: Death receptors: Signaling and modulation. Science 281: 1305-1308, 1998.
120. Du C, Fang M, Li Y, Li L and Wang X: Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition. Cell 102: 33-42, 2000.
121. Verhagen AM, Ekert PG, Pakusch M, Silke J, Connolly LM, Reid GE, Moritz RL, Simpson RJ and Vaux DL: Identification of DIABLO, a mammalian protein that promotes apoptosis by binding to and antagonizing IAP proteins. Cell 102: 43-53, 2000.
122. Cavigelli M, Li WW, Lin A, Su B, Yoshioka K and Karin M: The tumor promoter arsenite stimulates AP-1 activity by inhibiting a JNK phosphatase. EMBO J 15: 6269-6279, 1996.
123. Duckett CS, Perkins ND, Leung K, Agranoff AB and Nabel GJ: Cytokine induction of nuclear factor kappa B in cycling and growth-arrested cells. Evidence for cell cycle-independent activation. J Biol Chem 270: 18836-18840, 1995.
124. Perkins ND, Felzien LK, Betts JC, Leung K, Beach DH and Nabel GJ: Regulation of NF-kappaB by cyclin-dependent kinases associated with the p300 coactivator. Science 275: 523-527, 1997.
125. Otsuka G, Nagaya T, Saito K, Mizuno M, Yoshida J and Seo H: Inhibition of nuclear factor-kappaB activation confers sensitivity to tumor necrosis factor-alpha by impairment of cell cycle progression in human glioma cells. Cancer Res 59: 4446-4452, 1999.
126. Kaltschmidt B, Kaltschmidt C, Hehner SP, Droge W and Schmitz ML: Repression of NF-kappaB impairs HeLa cell proliferation by functional interference with cell cycle checkpoint regulators. Oncogene 18: 3213-3225, 1999.